Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
After finishing at $3.67 in the prior trading day, Clover Health Investments Corp (NASDAQ: CLOV) closed at $3.41, down -7.08%. In other words, the price has decreased by -$7.08 from its previous closing price. On the day, 13.65 million shares were traded. CLOV stock price reached its highest trading level at $3.755 during the session, while it also had its lowest trading level at $3.32.
Ratios:
Our goal is to gain a better understanding of CLOV by taking a closer look at its different ratios. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, UBS on October 07, 2024, initiated with a Neutral rating and assigned the stock a target price of $4.
On February 02, 2022, Cowen Upgraded its rating to Market Perform which previously was Underperform and also lowered its target price recommendation from $7 to $3.
On February 02, 2022, Canaccord Genuity started tracking the stock assigning a Buy rating and target price of $6.Canaccord Genuity initiated its Buy rating on February 02, 2022, with a $6 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 09 ’24 when Garipalli Vivek bought 531,700 shares for $1.88 per share. The transaction valued at 999,596 led to the insider holds 1,409,267 shares of the business.
Garipalli Vivek bought 877,567 shares of CLOV for $1,000,426 on Jun 17 ’24. The Director now owns 877,567 shares after completing the transaction at $1.14 per share. On May 16 ’24, another insider, Loengard Anna U, who serves as the Director of the company, bought 17,085 shares for $0.96 each. As a result, the insider paid 16,372 and bolstered with 15,600 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CLOV now has a Market Capitalization of 1705985536 and an Enterprise Value of 1376600448. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.02 while its Price-to-Book (P/B) ratio in mrq is 4.82. Its current Enterprise Value per Revenue stands at 0.651 whereas that against EBITDA is -17.967.
Stock Price History:
Over the past 52 weeks, CLOV has reached a high of $4.71, while it has fallen to a 52-week low of $0.61. The 50-Day Moving Average of the stock is -1.71%, while the 200-Day Moving Average is calculated to be 91.23%.
Shares Statistics:
The stock has traded on average 9.54M shares per day over the past 3-months and 8918960 shares per day over the last 10 days, according to various share statistics. A total of 393.27M shares are outstanding, with a floating share count of 372.95M. Insiders hold about 25.03% of the company’s shares, while institutions hold 15.46% stake in the company. Shares short for CLOV as of 1728950400 were 15745118 with a Short Ratio of 1.65, compared to 1726185600 on 25800908. Therefore, it implies a Short% of Shares Outstanding of 15745118 and a Short% of Float of 3.92.
